980 related articles for article (PubMed ID: 30790171)
21. [Diagnosis and treatment of cardiac transthyretin amyloidosis. Innovative therapy with tafamidis.].
Legrand D; Nyssen A; Jackers L; Brogneaux C; Pirotte I; Grayet D; Lacremans D; Magnée M
Rev Med Liege; 2022 Jan; 77(1):63-68. PubMed ID: 35029343
[TBL] [Abstract][Full Text] [Related]
22. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
[TBL] [Abstract][Full Text] [Related]
23. [Neurological manifestations of ATTR amyloidosis].
Pernice HF; Hahn K
Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
[TBL] [Abstract][Full Text] [Related]
24. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
25. Blood Proteomic Profiling in Inherited (ATTRm) and Acquired (ATTRwt) Forms of Transthyretin-Associated Cardiac Amyloidosis.
Chan GG; Koch CM; Connors LH
J Proteome Res; 2017 Apr; 16(4):1659-1668. PubMed ID: 28196416
[TBL] [Abstract][Full Text] [Related]
26. Reverse cardiac remodelling and dysfunction in A97S transthyretin cardiac amyloidosis after tafamidis treatment.
Wu YA; Tsai CH; Su MY; Chao CC; Cheng MF; Shun CT; Hsieh ST; Lin YH
ESC Heart Fail; 2022 Dec; 9(6):4335-4339. PubMed ID: 36128649
[TBL] [Abstract][Full Text] [Related]
27. The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types.
Varga C; Dorbala S; Lousada I; Polydefkis MJ; Wechalekar A; Maurer MS; Comenzo RL
Blood Rev; 2021 Jan; 45():100720. PubMed ID: 32616304
[TBL] [Abstract][Full Text] [Related]
28. Cardiac Amyloidosis Treatment.
Stern LK; Patel J
Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
[TBL] [Abstract][Full Text] [Related]
29. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
[TBL] [Abstract][Full Text] [Related]
30. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
[TBL] [Abstract][Full Text] [Related]
31. The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy.
Samjoo IA; Salvo EM; Tran D; Amass L; Stewart M; Cameron C
Curr Med Res Opin; 2020 May; 36(5):799-808. PubMed ID: 32011182
[No Abstract] [Full Text] [Related]
32. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.
Castaño A; Drachman BM; Judge D; Maurer MS
Heart Fail Rev; 2015 Mar; 20(2):163-78. PubMed ID: 25408161
[TBL] [Abstract][Full Text] [Related]
33. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.
Griffin JM; Maurer MS
Trends Cardiovasc Med; 2021 Jan; 31(1):59-66. PubMed ID: 31889610
[TBL] [Abstract][Full Text] [Related]
34. Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy.
Hänselmann A; Berliner D; Bauersachs J; Bavendiek U
Herz; 2022 Aug; 47(4):324-331. PubMed ID: 35674775
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of the Polish Cardiac Society.
Grzybowski J; Podolec P; Holcman K; Gawor-Prokopczyk M; Jankowska E; Kostkiewicz M; Dąbrowska-Kugacka A; Lipowska M; Mazurkiewicz Ł; Rajtar-Salwa R; Rubiś P; Straburzyńska-Migaj E; Szczygieł J; Mitkowski P
Kardiol Pol; 2023; 81(11):1167-1185. PubMed ID: 37768101
[TBL] [Abstract][Full Text] [Related]
36. Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review.
Cruz MW
Clin Auton Res; 2019 Sep; 29(Suppl 1):19-24. PubMed ID: 31407119
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).
Yilmaz A; Bauersachs J; Bengel F; Büchel R; Kindermann I; Klingel K; Knebel F; Meder B; Morbach C; Nagel E; Schulze-Bahr E; Aus dem Siepen F; Frey N
Clin Res Cardiol; 2021 Apr; 110(4):479-506. PubMed ID: 33459839
[TBL] [Abstract][Full Text] [Related]
38. [Transthyretin cardiac amyloidosis].
Eicher JC; Audia S; Damy T
Rev Med Interne; 2020 Oct; 41(10):673-683. PubMed ID: 32826087
[TBL] [Abstract][Full Text] [Related]
39. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types.
Nativi-Nicolau J; Maurer MS
Curr Opin Cardiol; 2018 Sep; 33(5):571-579. PubMed ID: 30015648
[TBL] [Abstract][Full Text] [Related]
40. Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy.
Galant NJ; Westermark P; Higaki JN; Chakrabartty A
Clin Sci (Lond); 2017 Mar; 131(5):395-409. PubMed ID: 28213611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
